Satyanarayana Chava – CEO, Laurus Labs, India
Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well…
Laurus Labs Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in India and internationally. It operates through Laurus Generics APIs, Laurus Generics Finished Dosage Forms (FDF), Laurus Synthesis, and Laurus Ingredients divisions.
The Laurus Generics APIs division develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), Hepatitis C, cardiovascular, antidiabetic, anti-asthmatic, gastroenterology, oncology, and ophthalmic therapeutic areas. The Laurus Generics Finished Dosage Forms division develops and manufactures oral solid formulations, such as ARVs, anti-diabetic, cardiovascular, and proton pump inhibitors.
The Laurus Synthesis division provides contract development and manufacturing services for pharmaceutical companies. The Laurus Ingredients division manufactures and sells speciality ingredients for use in the nutraceutical/dietary supplements and cosmeceutical products. In addition, it offers chemistry, IP development, business support, and related services to the pharmaceutical community. The company was incorporated in 2005 and is based in Hyderabad, India. Laurus Labs Limited is a subsidiary of Aptuit LLC.
Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
Watson is one the largest generic players in the US but the international presence of the company is still relatively modest. Watson does not have commercial operations in India but…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
The managing director of Encube Ethicals discusses contract manufacturing in India today, growing competition from China, and partnering with the world’s leading multinational pharma companies. Mr Dilip Shah from…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
Quintiles first established its operations in India in 1997, which was a very early stage in clinical research. What have been the main changes undergone by the country since then?…
Right after you started heading the India operations roughly 15 years ago, you had to oversee one the biggest mergers in the industry at that time. How challenging was that…
While we have seen many MNCs becoming increasingly interested in India, the story of Nycomed has been quite unique. Rather than starting off with marketing and sales offices, India was…
Two weeks ago, Lupin announced its annual results, portraying 6 years of sustained growth and a net profit up by 27%. How pleased were you with this performance, and were…
Compared to 5 years ago, MNCs have increased their presence in India. Some even have become market leaders, particularly through acquisitions of domestic players. How is this redistributing the game…
If we first take a step back and look at how Bharat Biotech was established, we see quite a remarkable story. It is rather exceptional to see scientists becoming entrepreneurs.…
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
See our Cookie Privacy Policy Here
